Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

SB-525 Continues to Show Encouraging Results for Hemophilia A in Phase 1/2 Trial

Investigational gene therapy SB-525 is well-tolerated and leads to a dose-dependent increase in factor VIII (FVIII), according to interim results from eight patients with severe hemophilia A enrolled in the Phase 1/2 Alta clinical trial. Data showed that patients who received the highest dose of...